Electromedical Technologies, Inc
EMEDdata completeness 100%5 fiscal years on fileData notes: no data for concept 'investmentsAtFairValue'; no data for concept 'netInvestmentIncome'; no data for concept 'gainsOnRealEstateSales'; no data for concept 'realEstateImpairment'; no data for concept 'dividendsPaid'; no data for concept 'incomeTaxExpense'; no data for concept 'pretaxIncome'
| Figure | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 |
|---|---|---|---|---|---|
| Revenue | $829,7371 | $737,9582 | $907,3623 | $1.15M4 | $1.35M4 |
| Net income | −$1.74M5 | −$3.87M6 | −$8.48M7 | −$3.47M8 | −$2.64M8 |
| Operating cash flow | −$280,7729 | −$1.34M10 | −$1.19M11 | −$773,33712 | −$1.42M12 |
| Capital expenditure | — | — | — | — | $149,70513 |
| Free cash flow (derived) | — | — | — | — | −$1.57M12 |
| Total debt | — | $732,26614 | $702,78015 | $671,52516 | $150,00017 |
| Cash & equivalents | $018 | $264,91319 | $383,17020 | $368,42521 | $87,70421 |
| Diluted shares | 17.9M | 22.3M | 51.0M | 133.6M | 377.2M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
10 shares is a claim on −$0.08 of net worth that earned you −$0.07 and generated −$0.04 of cash last year, against $0 of debt.
Not enough data in the filings for a return-on-capital reading.
seeing a moat in the numbers →Share count is up 2007% over 5 years — owners have been diluted. Worth asking what they got for it. Total debt has fallen 80% — deleveraging.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
Different models answer different questions — which to trust when →
- 10-K · period ending 2019-12-31 · accession 0001104659-21-043965 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2020-12-31 · accession 0001410578-22-000752 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2021-12-31 · accession 0001410578-23-000555 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2022-12-31 · accession 0001410578-24-000581 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2019-12-31 · accession 0001104659-21-043965 (NetIncomeLoss)
- 10-K · period ending 2020-12-31 · accession 0001410578-22-000752 (NetIncomeLoss)
- 10-K · period ending 2021-12-31 · accession 0001410578-23-000555 (NetIncomeLoss)
- 10-K · period ending 2022-12-31 · accession 0001410578-24-000581 (NetIncomeLoss)
- 10-K · period ending 2019-12-31 · accession 0001104659-21-043965 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2020-12-31 · accession 0001410578-22-000752 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2021-12-31 · accession 0001410578-23-000555 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2022-12-31 · accession 0001410578-24-000581 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2023-12-31 · accession 0001410578-24-000581 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2020-12-31 · accession 0001104659-21-043965 (LongTermDebt)
- 10-K · period ending 2021-12-31 · accession 0001410578-22-000752 (LongTermDebt)
- 10-K · period ending 2022-12-31 · accession 0001410578-23-000555 (LongTermDebt)
- 10-K · period ending 2023-12-31 · accession 0001410578-24-000581 (LongTermDebt)
- 10-K · period ending 2019-12-31 · accession 0001104659-21-043965 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2020-12-31 · accession 0001410578-22-000752 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2021-12-31 · accession 0001410578-23-000555 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2022-12-31 · accession 0001410578-24-000581 (CashAndCashEquivalentsAtCarryingValue)